EDMONTON, March 7 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), today announced that
its proprietary drug candidate MBP8298 delayed disease progression for five
years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response
genes. Treatment and follow-up of patients from a phase II clinical study
demonstrated that patients in this DR2 and DR4 responder group, who comprise
up to 75% of MS patients, had a median time to disease progression (worsening)
of 78 months compared to 18 months for patients who received placebo.
